Lv61
2090 积分 2022-09-21 加入
Genomic and nongenomic effects of glucocorticoids
4天前
已完结
Discovery of INCB123667, a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor for the treatment of cyclin E dysregulated cancers
7天前
已完结
Antibody drug conjugate combats inflammation
8天前
已完结
An anti–TNF–glucocorticoid receptor modulator antibody-drug conjugate is efficacious against immune-mediated inflammatory diseases
8天前
已完结
Discovery of ABBV-154, an anti-TNF Glucocorticoid Receptor Modulator Immunology Antibody-Drug Conjugate (iADC)
8天前
已完结
Advances And Challenges in Immunosuppressive Antibody Drug Conjugates
23天前
已完结
Targeting CDK2 and other novel cell cycle targets for breast cancer therapy
23天前
已完结
CELL CYCLE DYSREGULATION IN CANCER
1个月前
已完结
A patent review of anticancer CDK2 inhibitors (2017–present)
1个月前
已完结
Targeting cyclin-dependent kinase 2 (CDK2) interactions with cyclins and Speedy 1 (Spy1) for cancer and male contraception
1个月前
已完结
皖公网安备34019202002308
